{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:17:29Z","timestamp":1787836649844,"version":"build-2784847793"},"reference-count":88,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Bladder cancer is characterized by high recurrence and progression rates, posing a challenge to current diagnostic and treatment strategies. This review aims to provide a comprehensive overview of emerging technologies, including novel PET tracers, AI-assisted cystoscopy, theragnostics, and molecular biomarkers. Methods: We performed a narrative review of the recent literature focusing on innovations in imaging, AI, theragnostics, and biomarker research relevant to bladder cancer diagnosis and management. Results: Several novel PET tracers, such as 68Ga-PSMA and fibroblast activation protein inhibitor (FAPI), demonstrated potential in improving detection sensitivity. AI-enhanced cystoscopy has shown promise in real-time lesion detection, while theragnostic agents enable combined diagnostic and therapeutic applications. Advances in molecular biomarkers, including circulating Tumor DNA (ctDNA) and gene expression signatures, offer new avenues for patient stratification and monitoring. Conclusions: Integration of advanced imaging, AI, theragnostics, and biomarker analysis may transform bladder cancer management, supporting personalized and more effective care strategies.<\/jats:p>","DOI":"10.3390\/cancers17193261","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:51:13Z","timestamp":1759935073000},"page":"3261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-6209","authenticated-orcid":false,"given":"Eduardo","family":"Albers Acosta","sequence":"first","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8954-5351","authenticated-orcid":false,"given":"Lira","family":"Pelari Mici","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M\u00e1rquez","family":"G\u00fcemez","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Velasco Balanza","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Saavedra Centeno","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"P\u00e9rez P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Celada Luis","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Quicios Dorado","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario Ram\u00f3n y Cajal, IRYSIS, Universidad de Alcal\u00e1, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Espa\u00f1a Navarro","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Regional Universitario de M\u00e1laga, TAUS CLINICS, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Toquero Diez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria Romero","family":"Laorden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3427-2931","authenticated-orcid":false,"given":"Luis San Jos\u00e9","family":"Manso","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"European Association of Urology (2025). EAU Guidelines: Muscle-Invasive and Metastatic Bladder Cancer, European Association of Urology. Available online: https:\/\/uroweb.org\/guidelines."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bju.16471","article-title":"Advanced optical imaging techniques for bladder cancer detection and diagnosis: A systematic review","volume":"134","author":"Remmelink","year":"2024","journal-title":"BJU Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41585-024-00904-9","article-title":"Optimizing cystoscopy and TURBT: Enhanced imaging and artificial intelligence","volume":"22","author":"Shkolyar","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"ref_5","first-page":"562","article-title":"Diagnostic Evaluation of 18F-FDG PET\/CT Imaging in Recurrent or Residual Urinary Bladder Cancer: A Meta-Analysis","volume":"17","author":"Xue","year":"2020","journal-title":"Urol. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s00259-022-05761-5","article-title":"Feasibility of [68Ga]Ga-FAPI-46 PET\/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma","volume":"49","author":"Unterrainer","year":"2022","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2967\/jnumed.123.267260","article-title":"A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET\/CT in Genitourinary Cancers","volume":"65","author":"Hagens","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","article-title":"Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in Patients with Bladder Cancer","volume":"24","author":"Novruzov","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40291-024-00735-9","article-title":"Is There a Role for FAPI PET in Urological Cancers?","volume":"28","author":"Ortolan","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2967\/jnumed.123.266390","article-title":"Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer","volume":"65","author":"Koshkin","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s00259-024-06595-z","article-title":"[68Ga]Ga-FAPI-46 PET\/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: Initial experiences from a pilot analysis","volume":"51","author":"Unterrainer","year":"2024","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40644-018-0158-4","article-title":"11C-acetate PET\/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: A prospective multicenter study (ACEBIB trial)","volume":"18","author":"Salminen","year":"2018","journal-title":"Cancer Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00330-022-09270-9","article-title":"A machine-learning-based combination of criteria to detect bladder cancer lymph node metastasis on [18F]FDG PET\/CT: A pathology-controlled study","volume":"33","author":"Girard","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"van der Fels, C.A.M., Leliveld, A., Buikema, H., Heuvel, M.C.v.D., and de Jong, I.J. (2022). VEGF, EGFR and PSMA as possible imaging targets of lymph node metastases of urothelial carcinoma of the bladder. BMC Urol., 22.","DOI":"10.1186\/s12894-022-01157-7"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET\/CT Imaging of Advanced Urothelial Carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2019.08.032","article-title":"Augmented Bladder Tumor Detection Using Deep Learning","volume":"76","author":"Shkolyar","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_17","first-page":"361.e1","article-title":"Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry","volume":"36","author":"Daneshmand","year":"2018","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Russo, G.I., Sholklapper, T.N., Cocci, A., Broggi, G., Caltabiano, R., Smith, A.B., Lotan, Y., Morgia, G., Kamat, A.M., and Witjes, J.A. (2021). Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13174378"},{"key":"ref_19","first-page":"69","article-title":"Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature","volume":"17","author":"Paluch","year":"2025","journal-title":"Res. Rep. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1097\/JS9.0000000000000592","article-title":"Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: A systematic review and network meta-analysis","volume":"109","author":"Fan","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhu, M., Gu, Z., Chen, F., Chen, X., Wang, Y., and Zhao, G. (2024). Application of artificial intelligence in the diagnosis and treatment of urinary tumors. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1440626"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ali, N., Bolenz, C., Todenh\u00f6fer, T., Stenzel, A., Deetmar, P., Knoll, T., Porubsky, S., Hartmann, A., Popp, J., and Kriegmair, M.C. (2021). Deep learning-based classification of blue light cystoscopy imaging during transurethral resection of bladder tumors. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-91081-x"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/lsm.23788","article-title":"In vivo assessment of bladder cancer with diffuse reflectance and fluorescence spectroscopy: A comparative study","volume":"56","author":"Zlobina","year":"2024","journal-title":"Lasers Surg. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1089\/end.2021.0483","article-title":"Artificial Intelligence for Segmentation of Bladder Tumor Cystoscopic Images Performed by U-Net with Dilated Convolution","volume":"36","author":"Mutaguchi","year":"2022","journal-title":"J. Endourol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/end.2019.0509","article-title":"Support System of Cystoscopic Diagnosis for Bladder Cancer Based on Artificial Intelligence","volume":"34","author":"Ikeda","year":"2020","journal-title":"J. Endourol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1245\/s10434-025-17015-3","article-title":"Leveraging Deep Learning in Real-Time Intelligent Bladder Tumor Detection During Cystoscopy: A Diagnostic Study","volume":"32","author":"Ye","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/jnci\/djab179","article-title":"An Artificial Intelligence System for the Detection of Bladder Cancer via Cystoscopy: A Multicenter Diagnostic Study","volume":"114","author":"Wu","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kim, J., Ham, W.S., Koo, K.C., Lee, J., Ahn, H.K., Jeong, J.Y., Baek, S.Y., Lee, S.J., and Lee, K.S. (2024). Evaluation of the Diagnostic Efficacy of the AI-Based Software INF-M01 in Detecting Suspicious Areas of Bladder Cancer Using Cystoscopy Images. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237110"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1007\/s00261-024-04715-9","article-title":"A novel artificial intelligence segmentation model for early diagnosis of bladder tumors","volume":"50","author":"Li","year":"2024","journal-title":"Abdom. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104984","DOI":"10.1016\/j.ijmedinf.2023.104984","article-title":"A comparative study of attention mechanism based deep learning methods for bladder tumor segmentation","volume":"171","author":"Zhang","year":"2023","journal-title":"Int. J. Med. Inform."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s11517-024-03018-x","article-title":"A lightweight bladder tumor segmentation method based on attention mechanism","volume":"62","author":"Zhao","year":"2024","journal-title":"Med. Biol. Eng. Comput."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hwang, W.K., Jo, S.B., Han, D.E., Ahn, S.T., Oh, M.M., Park, H.S., Moon, D.G., Choi, I., Yang, Z., and Kim, J.W. (2024). Artificial Intelligence-Based Classification and Segmentation of Bladder Cancer in Cystoscope Images. Cancers, 17.","DOI":"10.3390\/cancers17010057"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e089125","DOI":"10.1136\/bmjopen-2024-089125","article-title":"Using artificial intelligence for bladder cancer detection during cystoscopy and its impact on clinical outcomes: A protocol for a systematic review and meta-analysis","volume":"14","author":"Baana","year":"2024","journal-title":"BMJ Open"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yoo, J.W., Koo, K.C., Chung, B.H., Baek, S.Y., Lee, S.J., Park, K.H., and Lee, K.S. (2022). Deep learning diagnostics for bladder tumor identification and grade prediction using RGB method. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-22797-7"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/end.2024.0250","article-title":"Selection of Convolutional Neural Network Model for Bladder Tumor Classification of Cystoscopy Images and Comparison with Humans","volume":"38","author":"Lee","year":"2024","journal-title":"J. Endourol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jia, X., Shkolyar, E., Laurie, M.A., Eminaga, O., Liao, J.C., and Xing, L. (2023). Tumor detection under cystoscopy with transformer-augmented deep learning algorithm. Phys. Med. Biol., 68.","DOI":"10.1088\/1361-6560\/ace499"},{"key":"ref_37","first-page":"747","article-title":"Real-time Detection of Bladder Cancer Using Augmented Cystoscopy with Deep Learning: A Pilot Study","volume":"37","author":"Chang","year":"2023","journal-title":"J. Endourol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00345-019-03059-0","article-title":"Application of artificial neural networks for automated analysis of cystoscopic images: A review of the current status and future prospects","volume":"38","author":"Negassi","year":"2020","journal-title":"World J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vitiello, A., Ferrara, F., Lasala, R., and Zovi, A. (2022). Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies. Cancers, 14.","DOI":"10.3390\/cancers14205167"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.seminoncol.2020.09.002","article-title":"Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies","volume":"47","author":"Sardana","year":"2020","journal-title":"Semin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bednova, O., and Leyton, J.V. (2020). Targeted Molecular Therapeutics for Bladder Cancer\u2014A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197268"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, Y., He, M., Li, J., and Li, L. (2025). Immunotherapeutic strategies for invasive bladder cancer: A comprehensive review. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1591379"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Michaud, \u00c9., Mansure, J.J., and Kassouf, W. (Br. J. Pharmacol., 2024). Integrating novel immunotherapeutic approaches in organ-preserving therapies for bladder cancer, Br. J. Pharmacol., early view.","DOI":"10.1111\/bph.16300"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e239003","DOI":"10.1148\/radiol.239003","article-title":"Emerging and Evolving Concepts in Cancer Immunotherapy Imaging","volume":"306","author":"Dercle","year":"2023","journal-title":"Radiology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1148\/radiol.212481","article-title":"18F FDG PET\/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer","volume":"304","author":"Hughes","year":"2022","journal-title":"Radiology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Huang, S., Huang, Y., Li, C., Liang, Y., Huang, M., Luo, R., and Liang, W. (2024). Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: A systematic review and meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1332213"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1038\/s41467-024-48480-1","article-title":"Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer","volume":"15","author":"Beckabir","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"German\u00e0, E., Pepe, L., Pizzimenti, C., Ballato, M., Pierconti, F., Tuccari, G., Ieni, A., Giuffr\u00e8, G., Fadda, G., and Fiorentino, V. (2024). Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126750"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Roviello, G., Catalano, M., Nobili, S., Santi, R., Mini, E., and Nesi, G. (2020). Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217935"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Leung, D., Bonacorsi, S., Smith, R.A., Weber, W., and Hayes, W. (2021). Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.698425"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Abenavoli, E.M., Linguanti, F., Calabretta, R., Bolton, R.C.D., Berti, V., and Lopci, E. (2023). Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors. Cancers, 15.","DOI":"10.3390\/cancers15235675"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2021","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: Updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_56","first-page":"3658","article-title":"PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation","volume":"130","author":"Martini","year":"2024","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2025.5724","article-title":"Unleashing the power of urine-based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review)","volume":"66","author":"Wan","year":"2025","journal-title":"Int. J. Oncol."},{"key":"ref_58","first-page":"3166","article-title":"Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer","volume":"6","author":"Lu","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lodewijk, I., Due\u00f1as, M., Rubio, C., Munera-Maravilla, E., Segovia, C., Bernardini, A., Teijeira, A., Paramio, J.M., and Su\u00e1rez-Cabrera, C. (2018). Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092514"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"59527","DOI":"10.18632\/oncotarget.18521","article-title":"The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: A meta-analysis of 30 published studies","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5152\/tud.2025.24135","article-title":"The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"50","author":"Liliana","year":"2025","journal-title":"Urol. Res. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11255-022-03406-y","article-title":"Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients","volume":"55","author":"Liu","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.esmoop.2022.100416","article-title":"Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer","volume":"7","author":"Beije","year":"2022","journal-title":"ESMO Open"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"501717","DOI":"10.1016\/j.acuro.2025.501717","article-title":"Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review","volume":"49","author":"Grosso","year":"2025","journal-title":"Actas Urol. Esp."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: A systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.juro.2016.12.010","article-title":"Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study","volume":"197","author":"Kavalieris","year":"2017","journal-title":"J. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Grimaldi, A.M., Lapucci, C., Salvatore, M., Incoronato, M., and Ferrari, M. (2022). Urinary miRNAs as a Diagnostic Tool for Bladder Cancer: A Systematic Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112766"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2217\/fon-2023-0922","article-title":"miRNA-143 as a potential biomarker in the detection of bladder cancer: A meta-analysis","volume":"20","author":"Li","year":"2024","journal-title":"Futur. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Su, Q., Wu, H., Zhang, Z., Lu, C., Zhang, L., and Zuo, L. (2021). Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.719863"},{"key":"ref_71","first-page":"628","article-title":"Prognostic role of circRNAs and RNA methylation enzymes in bladder cancer: A systematic review and meta-analysis of Chinese studies","volume":"43","author":"Ren","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wang, Y., Bhandary, P., Griffin, K., Moore, J.H., Li, X., and Wang, Z.P. (2025). Integrative multi-omics study identifies sex-specific molecular signatures and immune modulation in bladder cancer. Front. Bioinform., 5.","DOI":"10.3389\/fbinf.2025.1575790"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s10020-022-00462-z","article-title":"Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer","volume":"28","author":"Moisoiu","year":"2022","journal-title":"Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Chen, R., Pagano, I., Sun, Y., Murakami, K., Goodison, S., Vairavan, R., Tahsin, M., Black, P.C., Rosser, C.J., and Furuya, H. (2022). A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081801"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Pavan, N., and Scaggiante, B. (2024). Editorial: Liquid biopsy in the detection and prediction of outcomes in bladder cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1391466"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41585-025-01023-9","article-title":"Circulating tumour DNA and circulating tumour cells in bladder cancer\u2014From discovery to clinical implementation","volume":"22","author":"Lindskrog","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_78","first-page":"43","article-title":"Current role of radiomics and radiogenomics in predicting oncological outcomes in bladder cancer","volume":"19","author":"Temperley","year":"2024","journal-title":"Curr. Urol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","article-title":"Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma","volume":"126","author":"Shohdy","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Lee, J., Chen, F., Lopez-Beltran, A., Necchi, A., Cimadamore, A., Spiess, P.E., Li, R., Roy-Chowdhuri, S., Montironi, R., and Golijanin, D. (2025). Urinary Tumor DNA\u2013based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. Eur. Urol. Focus, in press.","DOI":"10.1016\/j.euf.2025.06.009"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Matuszczak, M., and Salagierski, M. (2020). Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093360"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000546014","article-title":"The value of circulating tumor DNA in the prognostic diagnosis of bladder cancer: A systematic review and meta-analysis","volume":"109","author":"Lu","year":"2025","journal-title":"Urol. Int."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Huang, P., Wang, J., Yu, Z., Lu, J., Sun, Z., and Chen, Z. (2025). Redefining bladder cancer treatment: Innovations in overcoming drug resistance and immune evasion. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1537808"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Ahangar, M., Mahjoubi, F., and Mowla, S.J. (2024). Bladder cancer biomarkers: Current approaches and future directions. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1453278"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e233020","DOI":"10.1148\/radiol.233020","article-title":"Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI","volume":"313","author":"Brembilla","year":"2024","journal-title":"Radiology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/14737159.2019.1680284","article-title":"Liquid biopsy in the clinical management of bladder cancer: Current status and future developments","volume":"20","author":"Kouba","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Koguchi, D., Matsumoto, K., Shiba, I., Harano, T., Okuda, S., Mori, K., Hirano, S., Kitajima, K., Ikeda, M., and Iwamura, M. (2022). Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169148"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:40Z","timestamp":1760035840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":88,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193261"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193261","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}